High Growth Tech Stocks To Watch In October 2024

In this article:

As global markets react to China's robust stimulus measures, U.S. stocks have reached record highs, buoyed by optimism in technology sectors and AI demand, despite some mixed economic indicators such as consumer confidence and housing data. In this context of heightened market activity and evolving economic conditions, identifying high growth tech stocks involves looking for companies that are well-positioned to capitalize on technological advancements and shifts in consumer behavior driven by these broader market trends.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Sarepta Therapeutics

23.58%

44.12%

★★★★★★

TG Therapeutics

28.39%

43.54%

★★★★★★

eWeLLLtd

26.52%

27.53%

★★★★★★

Seojin SystemLtd

33.61%

52.05%

★★★★★★

Medley

24.98%

30.36%

★★★★★★

Scandion Oncology

40.71%

75.34%

★★★★★★

KebNi

34.75%

86.11%

★★★★★★

Mental Health TechnologiesLtd

27.88%

79.61%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

Travere Therapeutics

26.51%

69.33%

★★★★★★

Click here to see the full list of 1279 stocks from our High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Grifols

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Grifols, S.A. is a plasma therapeutic company with operations in Spain, the United States, Canada, and internationally, and has a market cap of approximately €6.31 billion.

Operations: Grifols generates its revenue primarily from the Biopharma segment, which accounts for approximately €5.78 billion, followed by the Diagnostic segment with €651.33 million and Bio Supplies at €186.91 million.

Grifols, a key player in the biotech sector, is navigating a transformative phase with strategic executive shifts and robust R&D investment. With an impressive 28.3% projected annual earnings growth, the company significantly outpaces the broader Spanish market's 9.9%. This growth trajectory is bolstered by a 6% revenue increase forecast, also above Spain's average. Recent leadership changes aim to enhance corporate governance and focus on operational efficiencies, aligning with Grifols' commitment to innovation in biotechnology solutions and financial health improvement strategies.

BME:GRF Revenue and Expenses Breakdown as at Oct 2024
BME:GRF Revenue and Expenses Breakdown as at Oct 2024

argenx

Simply Wall St Growth Rating: ★★★★★★

Overview: argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases across the United States, Japan, Europe, the Middle East, Africa, and China with a market cap of €29.70 billion.

Operations: argenx SE generates revenue primarily from its biotechnology segment, amounting to $1.66 billion. The company is focused on developing therapies for autoimmune diseases across multiple regions, including the United States and Asia.

argenx, amid a competitive landscape, stands out with its robust R&D commitment and promising clinical outcomes. The company's revenue is projected to surge by 26.4% annually, significantly outpacing the Belgian market's growth of 7.5%. This financial trajectory is underpinned by a striking expected annual profit growth of 58.44%, signaling potential profitability within three years. Recent breakthroughs include the FDA approval of VYVGART Hytrulo for CIDP treatment, reflecting argenx's focus on innovative autoimmune therapies that meet critical healthcare needs.

ENXTBR:ARGX Revenue and Expenses Breakdown as at Oct 2024
ENXTBR:ARGX Revenue and Expenses Breakdown as at Oct 2024

Hebei Sinopack Electronic TechnologyLtd

Simply Wall St Growth Rating: ★★★★★☆

Overview: Hebei Sinopack Electronic Technology Co., Ltd. is engaged in the production of electronic ceramic materials, components, and third-generation semiconductor devices and modules, with a market capitalization of approximately CN¥20.99 billion.

Operations: Sinopack's revenue is primarily derived from electronic ceramic materials and components, contributing CN¥1.74 billion, and third-generation semiconductor devices and modules, generating CN¥1.43 billion.

Hebei Sinopack Electronic TechnologyLtd. is navigating a challenging landscape with its robust R&D investment, which has surged to 31.8% of its revenue, aligning with an aggressive growth trajectory in tech innovation. Despite a slight dip in year-over-year earnings, the company's revenue growth remains strong at 30.2%, outpacing the broader Chinese market's expansion rate. Recently, shareholders convened to amend corporate statutes, potentially paving the way for strategic pivots that could enhance operational efficiencies and market responsiveness. This backdrop of solid revenue gains and substantial reinvestment in development projects positions Hebei Sinopack to capitalize on evolving tech demands while fortifying its competitive edge in high-tech sectors.

SZSE:003031 Earnings and Revenue Growth as at Oct 2024
SZSE:003031 Earnings and Revenue Growth as at Oct 2024

Summing It All Up

Interested In Other Possibilities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BME:GRF ENXTBR:ARGX and SZSE:003031.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Advertisement